Homocysteine and Parkinson's disease

A dangerous liaison?

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Homocysteine, a sulphur-containing amino acid formed by demethylation of methionine, is involved in numerous processes of methyl group transfer, all playing pivotal roles in the biochemistry of the human body. Increased levels of plasma homocysteine (hyperhomocysteinemia) - which may result from a deficiency of folate, vitamin B6 or B12 or mutations in enzymes regulating the catabolism of homocysteine - are associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy and epileptic seizures). Recent evidence suggests that changes in the metabolic fate of homocysteine, leading to hyperhomocysteinemia, may also play a role in the pathophysiology of neurodegenerative disorders, particularly Parkinson's disease (PD). The nervous system might be particularly sensitive to homocysteine, due to the excitotoxic-like properties of the amino acid. However, experimental findings have shown that homocysteine does not seem to posses direct, cytotoxic activity, while the amino acid has proven able to synergize with more specific neurotoxic insults. Hyperhomocysteinemia has been repeatedly reported in PD patients; the increase, however, seems mostly related to the methylated catabolism of l-Dopa, the main pharmacological treatment of PD. Therefore, hyperhomocysteinemia may not be specific to movement disorders or other neurological diseases, the condition being, in fact, rather the result of the combinations of different factors, mainly metabolic, but also genetic and pharmacological, intervening in the neurodegenerative process.

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalJournal of the Neurological Sciences
Volume257
Issue number1-2
DOIs
Publication statusPublished - Jun 15 2007

Fingerprint

Hyperhomocysteinemia
Homocysteine
Parkinson Disease
Vitamin B 6 Deficiency
Pharmacology
Sulfur Amino Acids
Vitamin B 12 Deficiency
Amino Acids
Dihydroxyphenylalanine
Group Processes
Movement Disorders
Human Body
Folic Acid
Intellectual Disability
Neurodegenerative Diseases
Methionine
Biochemistry
Nervous System
Atrophy
Epilepsy

Keywords

  • Cytotoxicity
  • Folic acid
  • l-Dopa
  • Methylation
  • Movement disorders
  • Neurodegeneration
  • Vitamin B12

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Neuroscience(all)
  • Developmental Neuroscience
  • Neurology

Cite this

Homocysteine and Parkinson's disease : A dangerous liaison? / Martignoni, E.; Tassorelli, C.; Nappi, G.; Zangaglia, R.; Pacchetti, C.; Blandini, F.

In: Journal of the Neurological Sciences, Vol. 257, No. 1-2, 15.06.2007, p. 31-37.

Research output: Contribution to journalArticle

@article{cd76f2cf456f4aa0a1dd4627268fdf1c,
title = "Homocysteine and Parkinson's disease: A dangerous liaison?",
abstract = "Homocysteine, a sulphur-containing amino acid formed by demethylation of methionine, is involved in numerous processes of methyl group transfer, all playing pivotal roles in the biochemistry of the human body. Increased levels of plasma homocysteine (hyperhomocysteinemia) - which may result from a deficiency of folate, vitamin B6 or B12 or mutations in enzymes regulating the catabolism of homocysteine - are associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy and epileptic seizures). Recent evidence suggests that changes in the metabolic fate of homocysteine, leading to hyperhomocysteinemia, may also play a role in the pathophysiology of neurodegenerative disorders, particularly Parkinson's disease (PD). The nervous system might be particularly sensitive to homocysteine, due to the excitotoxic-like properties of the amino acid. However, experimental findings have shown that homocysteine does not seem to posses direct, cytotoxic activity, while the amino acid has proven able to synergize with more specific neurotoxic insults. Hyperhomocysteinemia has been repeatedly reported in PD patients; the increase, however, seems mostly related to the methylated catabolism of l-Dopa, the main pharmacological treatment of PD. Therefore, hyperhomocysteinemia may not be specific to movement disorders or other neurological diseases, the condition being, in fact, rather the result of the combinations of different factors, mainly metabolic, but also genetic and pharmacological, intervening in the neurodegenerative process.",
keywords = "Cytotoxicity, Folic acid, l-Dopa, Methylation, Movement disorders, Neurodegeneration, Vitamin B12",
author = "E. Martignoni and C. Tassorelli and G. Nappi and R. Zangaglia and C. Pacchetti and F. Blandini",
year = "2007",
month = "6",
day = "15",
doi = "10.1016/j.jns.2007.01.028",
language = "English",
volume = "257",
pages = "31--37",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Homocysteine and Parkinson's disease

T2 - A dangerous liaison?

AU - Martignoni, E.

AU - Tassorelli, C.

AU - Nappi, G.

AU - Zangaglia, R.

AU - Pacchetti, C.

AU - Blandini, F.

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Homocysteine, a sulphur-containing amino acid formed by demethylation of methionine, is involved in numerous processes of methyl group transfer, all playing pivotal roles in the biochemistry of the human body. Increased levels of plasma homocysteine (hyperhomocysteinemia) - which may result from a deficiency of folate, vitamin B6 or B12 or mutations in enzymes regulating the catabolism of homocysteine - are associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy and epileptic seizures). Recent evidence suggests that changes in the metabolic fate of homocysteine, leading to hyperhomocysteinemia, may also play a role in the pathophysiology of neurodegenerative disorders, particularly Parkinson's disease (PD). The nervous system might be particularly sensitive to homocysteine, due to the excitotoxic-like properties of the amino acid. However, experimental findings have shown that homocysteine does not seem to posses direct, cytotoxic activity, while the amino acid has proven able to synergize with more specific neurotoxic insults. Hyperhomocysteinemia has been repeatedly reported in PD patients; the increase, however, seems mostly related to the methylated catabolism of l-Dopa, the main pharmacological treatment of PD. Therefore, hyperhomocysteinemia may not be specific to movement disorders or other neurological diseases, the condition being, in fact, rather the result of the combinations of different factors, mainly metabolic, but also genetic and pharmacological, intervening in the neurodegenerative process.

AB - Homocysteine, a sulphur-containing amino acid formed by demethylation of methionine, is involved in numerous processes of methyl group transfer, all playing pivotal roles in the biochemistry of the human body. Increased levels of plasma homocysteine (hyperhomocysteinemia) - which may result from a deficiency of folate, vitamin B6 or B12 or mutations in enzymes regulating the catabolism of homocysteine - are associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy and epileptic seizures). Recent evidence suggests that changes in the metabolic fate of homocysteine, leading to hyperhomocysteinemia, may also play a role in the pathophysiology of neurodegenerative disorders, particularly Parkinson's disease (PD). The nervous system might be particularly sensitive to homocysteine, due to the excitotoxic-like properties of the amino acid. However, experimental findings have shown that homocysteine does not seem to posses direct, cytotoxic activity, while the amino acid has proven able to synergize with more specific neurotoxic insults. Hyperhomocysteinemia has been repeatedly reported in PD patients; the increase, however, seems mostly related to the methylated catabolism of l-Dopa, the main pharmacological treatment of PD. Therefore, hyperhomocysteinemia may not be specific to movement disorders or other neurological diseases, the condition being, in fact, rather the result of the combinations of different factors, mainly metabolic, but also genetic and pharmacological, intervening in the neurodegenerative process.

KW - Cytotoxicity

KW - Folic acid

KW - l-Dopa

KW - Methylation

KW - Movement disorders

KW - Neurodegeneration

KW - Vitamin B12

UR - http://www.scopus.com/inward/record.url?scp=34249796691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249796691&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2007.01.028

DO - 10.1016/j.jns.2007.01.028

M3 - Article

VL - 257

SP - 31

EP - 37

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -